A Comprehensive Review of Naringenin, a Promising Phytochemical with Therapeutic Potential

키워드

참고문헌 (173)

1. "Cancer"[URL]
2. Rodriguez-Casado A, "The health potential of fruits and vegetables phytochemicals : notable examples", Crit. Rev. Food Sci. Nutr, 56, pp.1097~1107 (2016)
3. Norat T, "European code against cancer 4th edition : diet and cancer", Cancer Epidemiol, 39(Suppl 1), pp.S56~S66 (2015)
4. Guarente L, "Sirtuins as potential targets for metabolic syndrome", Nature, 444, pp.868~874 (2006)
5. Luo J, "Dietary anti-aging polyphenols and potential mechanisms", Antioxidants(Basel), 10, pp.283~ (2021)
6. Santos AL, "Protein posttranslational modifications : roles in aging and age-related disease", Oxid. Med. Cell. Longev, 2017, pp.5716409~ (2017)
7. Reith W, "Neurodegenerative diseases", Radiologe, 58, pp.241~258 (2018)
8. Li Z, "Polyphenols : natural food grade biomolecules for treating neurodegenerative diseases from a multi-target perspective", Front. Nutr, 10, pp.1139558~ (2023)
9. Patra S, "Dietary polyphenols in chemoprevention and synergistic effect in cancer : clinical evidences and molecular mechanisms of action", Phytomedicine, 90, pp.153554~ (2021)
10. Shohag S, "Perspectives on the molecular mediators of oxidative stress and antioxidant strategies in the context of neuroprotection and neurolongevity : an extensive review", Oxid. Med. Cell Longev, 2022, pp.7743705~ (2022)
11. Rivas F, "Effects of polyphenols in aging and neurodegeneration associated with oxidative stress", Curr. Med. Chem, 29, pp.1045~1060 (2022)
12. Tufarelli V, "Dietary phenolic compounds : biochemistry, metabolism and significance in animal and human health", Curr. Drug Metab, 18, pp.905~913 (2017)
13. Teng H, "Polyphenols and bioavailability : an update", Crit. Rev. Food Sci. Nutr, 59, pp.2040~2051 (2019)
14. Di Lorenzo C, "Polyphenols and human health : the role of bioavailability", Nutrients, 13, pp.273~ (2021)
15. Barreca D, "Flavanones : citrus phytochemical with health-promoting properties", Biofactors, 43, pp.495~506 (2017)
16. Ramesh E, "Naringin induces death receptor and mitochondria-mediated apoptosis in human cervical cancer(SiHa)cells", Food Chem. Toxicol, 51, pp.97~105 (2013)
17. Esaki S, "Preparation and taste of certain glycosides of flavanones and of dihydrochalcones", Biosci. Biotechnol. Biochem, 58, pp.1479~1485 (1994)
18. Shin W, "Structure of(R, S)-hesperetin monohydrate", Acta Crystallogr. Sec. C, 43, pp.1946~1949 (1987)
19. Tripoli E, "Citrus flavonoids : molecular structure, biological activity and nutritional properties : a review", Food Chem, 104, pp.466~479 (2007)
20. Yao LH, "Flavonoids in food and their health benefits", Plant Foods Hum. Nutr, 59, pp.113~122 (2004)
21. Graf BA, "Flavonols, flavones, flavanones, and human health : epidemiological evidence", J. Med. Food, 8, pp.281~290 (2005)
22. "USDA Database for the Flavonoid Content of Selected Foods, Release 3.3" (2018)[URL]
23. Ribeiro MH, "Naringinases : occurrence, characteristics, and applications", Appl. Microbiol. Biotechnol, 90, pp.1883~1895 (2011)
24. Yusof S, "Naringin content in local citrus fruits", Food Chem, 37, pp.113~121 (1990)
25. Zhang L, "Solubilities of naringin and naringenin in different solvents and dissociation constants of naringenin", J. Chem. Eng. Data, 60, pp.932~940 (2015)
26. Justesen U, "Quantitative analysis of flavonols, flavones, and flavanones in fruits, vegetables and beverages by high-performance liquid chromatography with photo-diode array and mass spectrometric detection", J. Chromatogr. A, 799, pp.101~110 (1998)
27. Nait Chabane M, "Quercetin and naringenin transport across human intestinal Caco-2 cells", J. Pharm. Pharmacol, 61, pp.1473~1483 (2009)
28. Xu H, "Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides", Mol. Pharm, 6, pp.1703~1715 (2009)
29. Kanaze FI, "Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects", Eur. J. Clin. Nutr, 61, pp.472~477 (2007)
30. Spencer JPE, "Flavonoids and Related Compounds : Bioavailability and Function" (2012), CRC Press
31. Lin SP, "Tissue distribution of naringenin conjugated metabolites following repeated dosing of naringin to rats", Biomed. (Taipei), 4, pp.16~ (2014)
32. Youdim KA, "Flavonoid permeability across an in situ model of the bloodbrain barrier", Free Radic. Biol. Med, 36, pp.592~604 (2004)
33. Youdim KA, "Interaction between flavonoids and the blood–brain barrier : in vitro studies", J. Neurochem, 85, pp.180~192 (2003)
34. Peng HW, "Determination of naringenin and its glucuronide conjugate in rat plasma and brain tissue by high-performance liquid chromatography", J. Chromatogr. B Biomed. Sci. Appl, 714, pp.369~374 (1998)
35. Zeng X, "Pharmacokinetics, tissue distribution, metabolism, and excretion of naringin in aged rats", Front. Pharmacol, 10, pp.34~ (2019)
36. Chen T, "Simultaneously quantitative analysis of naringin and its major human gut microbial metabolites naringenin and 3-(4'-Hydroxyphenyl)propanoic acid via stable isotope deuterium-labeling coupled with RRLC-MS", MS method, 2019, pp.24, 4287~
37. Braune A, "An NADH-dependent reductase from Eubacterium ramulus catalyzes the stereospecific heteroring cleavage of flavanones and flavanonols", Appl. Environ. Microbiol, 85, pp.e01233-19~ (2019)
38. Jeon SM, "Hypocholesterolemic and antioxidative effects of naringenin and its two metabolites in high-cholesterol fed rats", Transl. Res, 149, pp.15~21 (2007)
39. Pereira-Caro G, "Chronic administration of a microencapsulated probiotic enhances the bioavailability of orange juice flavanones in humans", Free Radic. Biol. Med, 84, pp.206~214 (2015)
40. Ranka S, "Development of a food frequency questionnaire for the assessment of quercetin and naringenin intake", Eur. J. Clin. Nutr, 62, pp.1131~1138 (2008)
41. Xu HY, "Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides", Mol. Pharm, 6, pp.1703~1715 (2009)
42. Torre LA, "Global cancer incidence and mortality rates and trends--An update", Cancer Epidemiol. Biomarkers Prev, 25, pp.16~27 (2016)
43. Kawaii S, "Antiproliferative effects of the readily extractable fractions prepared from various citrus juices on several cancer cell lines", J. Agric. Food Chem, 47, pp.2509~2512 (1999)
44. KAWAII S, "Antiproliferative activity of flavonoids on several cancer cell lines", Biosci. Biotechnol. Biochem, 63, pp.896~899 (1999)
45. Siegel RL, "Cancer statistics, 2023", CA Cancer J. Clin, 73, pp.17~48 (2023)
46. Rajamanickam S, "Natural products and colon cancer : current status and future prospects", Drug Dev. Res, 69, pp.460~471 (2008)
47. Frydoonfar HR, "The variable effect on proliferation of a colon cancer cell line by the citrus fruit flavonoid Naringenin", Colorectal. Dis, 5, pp.149~152 (2003)
48. Zhao Y, "6-C-(E-phenylethenyl)naringenin induces cell growth inhibition and cytoprotective autophagy in colon cancer cells", Eur. J. Cancer, 68, pp.38~50 (2016)
49. Song HM, "Anti-proliferative effect of naringenin through p38-dependent downregulation of cyclin D1 in human colorectal cancer cells", Biomol. Ther, 23, pp.339~344 (2015)
50. Raeisi S, "Naringenin-loaded nano-structured lipid carrier fortifies oxaliplatin-dependent apoptosis in HT-29 cell line", Process Biochem, 83, pp.168~175 (2019)
51. Sung H, "Global Cancer Statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J. Clin, 71, pp.209~249 (2021)
52. Tan P, "Genetics and molecular pathogenesis of gastric adenocarcinoma", Gastroenterology, 149, pp.1153~1162 (2015)
53. Tramacere I, "A meta-analysis on alcohol drinking and gastric cancer risk", Ann. Oncol, 23, pp.28~36 (2012)
54. Lordick F, "Gastric cancer : ESMO clinical practice guideline for diagnosis, treatment and follow-up", Ann. Oncol, 33, pp.1005~1020 (2022)
55. Lu L, "A global assessment of recent trends in gastrointestinal cancer and lifestyle-associated risk factors", Cancer Commun(Lond), 41, pp.1137~1151 (2021)
56. Bao L, "Naringenin inhibits proliferation, migration, and invasion as well as induces apoptosis of gastric cancer SGC7901 cell line by downregulation of AKT pathway", Tumor Biol, 37, pp.11365~11374 (2016)
57. Lahiri A, "Lung cancer immunotherapy : progress, pitfalls, and promises", Mol. Cancer, 22, pp.40~ (2023)
58. Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J. Clin, 68, pp.394~424 (2018)
59. Kanwal M, "Familial risk for lung cancer(Review)", Onco. Lett, 13, pp.535~542 (2017)
60. Qin L, "Naringenin reduces lung metastasis in a breast cancer resection model", Protein Cell, 2, pp.507~516 (2011)
61. Du G, "Naringenin : a potential immunomodulator for inhibiting lung fibrosis and metastasis", Cancer Res, 69, pp.3205~3212 (2009)
62. Chang HL, "Naringenin inhibits migration of lung cancer cells via the inhibition of matrix metalloproteinases-2 and-9", Exp. Ther. Med, 13, pp.739~744 (2017)
63. Jin CY, "Naringenin up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer A549 cells", Mol. Nutr. Food Res, 55, pp.300~309 (2011)
64. Liu X, "Synergism antiproliferative effects of apigenin and naringenin in NSCLC cells", Molecules, 28, pp.4947~ (2023)
65. Pateliya B, "Combining naringenin and metformin with doxorubicin enhances anticancer activity against triple-negative breast cancer in vitro and in vivo", Eur. J. Pharmacol, 891, pp.173725~ (2021)
66. Noori S, "Naringenin and cryptotanshinone shift the immune response towards Th1 and modulate T regulatory cells via JAK2", STAT3 pathway in breast cancer, 2022, pp.22, 145~
67. Zhang F, "Naringenin prevents TGF-beta1 secretion from breast cancer and suppresses pulmonary metastasis by inhibiting PKC activation", Breast Cancer Res, 18, pp.38~ (2016)
68. Wang R, "Naringenin has a chemoprotective effect in MDA-MB-231 breast cancer cells via inhibition of caspase-3 and-9 activities", Oncol. Lett, 17, pp.1217~1222 (2019)
69. Harmon AW, "Naringenin inhibits glucose uptake in MCF-7 breast cancer cells : a mechanism for impaired cellular proliferation", Breast Cancer Res. Treat, 85, pp.103~110 (2004)
70. "Zhongguo Zhong Yao Za Zhi", 2015, 1144~1150
71. Jayson GC, "Ovarian cancer", Lancet, 384, pp.1376~1388 (2014)
72. Lin C, "Naringenin suppresses epithelial ovarian cancer by inhibiting proliferation and modulating gut microbiota", Phytomedicine, 106, pp.154401~ (2022)
73. Cohen PA, "Cervical cancer", Lancet, 393, pp.169~182 (2019)
74. Krishnakumar N, "Enhanced anticancer activity of naringenin-loaded nanoparticles in human cervical(HeLa)cancer cells", Biomed. Prevent. Nutr, 1, pp.223~231 (2011)
75. Ferlay J, "Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN 2012", Int. J. Cancer, 136, pp.E359~E386 (2015)
76. Liao ACH, "Naringenin inhibits migration of bladder cancer cells through downregulation of AKT and MMP-2", Mol. Med. Rep, 10, pp.1531~1536 (2014)
77. Nguyen-Nielsen M, "Diagnostic and therapeutic strategies for prostate cancer", Semin. Nucl. Med, 46, pp.484~490 (2016)
78. Han KY, "Naringenin attenuated prostate cancer invasion via reversal of epithelial-to-mesenchymal transition and inhibited uPA activity", Anticancer Res, 38, pp.6753~6758 (2018)
79. Gumushan Aktas H, "Naringenin inhibits prostate cancer metastasis by blocking voltage-gated sodium channels", Biomed Pharmacother, 106, pp.770~775 (2018)
80. Lim W, "Naringenin-induced apoptotic cell death in prostate cancer cells is mediated via the PI3K", AKT and MAPK signaling pathways, 2016, pp.118, 1118~1131
81. Yang YM, "Inflammation and liver cancer : molecular mechanisms and therapeutic targets", Semin. Liver Dis, 39, pp.26~42 (2019)
82. Arul D, "Inhibitory effect of naringenin(citrus flavonone)on N-nitrosodiethylamine induced hepatocarcinogenesis in rats", Biochem. Biophys. Res. Commun, 434, pp.203~209 (2013)
83. Thangavel P, "Antiproliferative and apoptotic effects of naringin on diethylnitrosamine induced hepatocellular carcinoma in rats", Biomed. Aging Pathol, 3, pp.59~64 (2013)
84. Yen HR, "Naringenin suppresses TPA-induced tumor invasion by suppressing multiple signal transduction pathways in human hepatocellular carcinoma cells", Chem. Biol. Interact, 235, pp.1~9 (2015)
85. Kang Q, "6-C-(E-Phenylethenyl)Naringenin attenuates the stemness of hepatocellular carcinoma cells by suppressing Wnt", β-catenin signaling, 2019, pp.67, 13939~13947
86. Pan P, "An immunological perspective for preventing cancer with berries", J. Berry Res, 8, pp.163~175 (2018)
87. Lou C, "Naringenin decreases invasiveness and metastasis by inhibiting TGFbeta-induced epithelial to mesenchymal transition in pancreatic cancer cells", PLoS One, 7, pp.e50956~ (2012)
88. Lee J, "Combined administration of naringenin and hesperetin with optimal ratio maximizes the anticancer effect in human pancreatic cancer via down regulation of FAK and p38 signaling pathway", Phytomedicine, 58, pp.152762~ (2019)
89. Park HJ, "Naringenin causes ASK1-induced apoptosis via reactive oxygen species in human pancreatic cancer cells", Food Chem. Toxicol, 99, pp.1~8 (2017)
90. Force USPST, "Screening for skin cancer : US preventive services task force recommendation statement", JAMA, 329, pp.1290~1295 (2023)
91. Ahamad MS, "Induction of apoptosis and antiproliferative activity of naringenin in human epidermoid carcinoma cell through ROS generation and cell cycle arrest", PLoS One, 9, pp.e110003~ (2014)
92. Kumar R, "Naringenin suppresses chemically induced skin cancer in two-stage skin carcinogenesis mouse model", Nutr. Cancer, 72, pp.976~983 (2020)
93. Pafumi I, "Naringenin impairs two-pore channel 2 activity and inhibits VEGF-induced angiogenesis", Sci. Rep, 7, pp.5121~ (2017)
94. Manna P, "Contribution of type 1 diabetes to rat liver dysfunction and cellular damage via activation of NOS, PARP, IkappaBalpha", NF-kappaB, MAPKs, and mitochondria-dependent pathways : prophylactic role of arjunolic acid, 2010, pp.48, 1465~1484
95. Zhang C, "Diabetes-induced hepatic pathogenic damage, inflammation, oxidative stress, and insulin resistance was exacerbated in zinc deficient mouse model", PLoS One, 7, pp.e49257~ (2012)
96. Gowd V, "Erythrocytes in the combined milieu of high glucose and high cholesterol shows glycosaminoglycandependent cytoadherence to extracellular matrix components", Int. J. Biol. Macromol, 73, pp.182~188 (2015)
97. Joladarashi D, "Diabetes results in structural alteration of chondroitin sulfate", dermatan sulfate in the rat kidney : effects on the binding to extracellular matrix components, 2011, pp.21, 960~972
98. Ritz E, "Diabetic nephropathy", Saudi J. Kidney Dis. Transpl, 17, pp.481~490 (2006)
99. Kam J, "Dietary interventions for type 2 diabetes : how millet comes to help", Front. Plant Sci, 7, pp.1454~ (2016)
100. Ortiz-Andrade RR, "Antidiabetic and toxicological evaluations of naringenin in normoglycaemic and NIDDM rat models and its implications on extra-pancreatic glucose regulation", Diabetes Obes. Metab, 10, pp.1097~1104 (2008)
101. Tsai SJ, "Anti-inflammatory and antifibrotic effects of naringenin in diabetic mice", J. Agric. Food Chem, 60, pp.514~521 (2012)
102. Orsolic N, "DNA-protective effects of quercetin or naringenin in alloxan-induced diabetic mice", Eur. J. Pharmacol, 656, pp.110~118 (2011)
103. Kannappan S, "Naringenin enhances insulin-stimulated tyrosine phosphorylation and improves the cellular actions of insulin in a dietary model of metabolic syndrome", Eur. J. Nutr, 49, pp.101~109 (2010)
104. Priscilla DH, "Naringenin inhibits alpha-glucosidase activity : a promising strategy for the regulation of postprandial hyperglycemia in high fat diet fed streptozotocin induced diabetic rats", Chem. Biol. Interact, 210, pp.77~85 (2014)
105. Mutlur Krishnamoorthy R, "Polyphenols activate energy sensing network in insulin resistant models", Chem. Biol. Interact, 275, pp.95~107 (2017)
106. Burke AC, "Naringenin supplementation to a chow Diet enhances energy expenditure and fatty acid oxidation, and reduces adiposity in lean, pair-fed Ldlr(-", -)mice, 2019, pp.63, e1800833~
107. Zygmunt K, "Naringenin, a citrus flavonoid, increases muscle cell glucose uptake via AMPK", Biochem. Biophys. Res. Commun, 398, pp.178~183 (2010)
108. Bhattacharya S, "Caffeic acid, naringenin and quercetin enhance glucose-stimulated insulin secretion and glucose sensitivity in INS-1E cells", Diabetes Obes. Metab, 16, pp.602~612 (2014)
109. von dem Knesebeck O, "Public beliefs about causes of obesity in the USA and in Germany", Int. J. Public Health, 64, pp.1139~1146 (2019)
110. Ruhm CJ, "Understanding overeating and obesity", J. Health Economics, 31, pp.781~796 (2012)
111. Lu SX, "Combined effects of hypertension, hyperlipidemia, and diabetes mellitus on the presence and severity of carotid atherosclerosis in community-dwelling elders : a community-based study", J. Chin. Med. Assoc, 86, pp.220~226 (2023)
112. Engin A, "The definition and prevalence of obesity and metabolic syndrome", Adv. Exp. Med. Biol, 960, pp.1~17 (2017)
113. Klop B, "Dyslipidemia in obesity : mechanisms and potential targets", Nutrients, 5, pp.1218~1240 (2013)
114. Rakhra V, "Obesity and the Western diet : how We got here", Mo Med, 117, pp.536~538 (2020)
115. Lee SH, "Cholesterol-lowering activity of naringenin via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase and acyl coenzyme A : cholesterol acyltransferase in rats", Ann. Nutr. Metab, 43, pp.173~180 (1999)
116. Cho KW, "Dietary naringenin increases hepatic peroxisome proliferators-activated receptor alpha protein expression and decreases plasma triglyceride and adiposity in rats", Eur. J. Nutr, 50, pp.81~88 (2011)
117. Zar Kalai F, "Antiobesity effects of an edible halophyte Nitraria retusa forssk in 3T3-L1 preadipocyte differentiation and in C57B6J", L mice fed a high fat diet-induced obesity, 2013, pp.2013, 368658~
118. Yoshida H, "Citrus flavonoid naringenin inhibits TLR2expression in adipocytes", J. Nutr. Biochem, 24, pp.1276~1284 (2013)
119. Cai XY, "Naringenin inhibits lipid accumulation by activating the AMPK pathway in vivo and in vitro", Food Sci. Hum. Wellness, 12, pp.1174~1183 (2023)
120. Assini JM, "Naringenin prevents cholesterol-induced systemic inflammation, metabolic dysregulation, and atherosclerosis in Ldlr(-)", (-)mice, 2013, pp.54, 711~724
121. Mulvihill EE, "Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance", Diabetes, 58, pp.2198~2210 (2009)
122. Richard AJ, "Naringenin inhibits adipogenesis and reduces insulin sensitivity and adiponectin expression in adipocytes", Evid. Based. Complement. Alternat. Med, 2013, pp.549750~ (2013)
123. Mills KT, "The global epidemiology of hypertension", Nat. Rev. Nephrol, 16, pp.223~237 (2020)
124. Mowry FE, "Neuroinflammation in hypertension : the renin-angiotensin system versus pro-resolution pathways", Pharmacol. Res, 144, pp.279~291 (2019)
125. Carey RM, "Prevention and control of hypertension : JACC health promotion series", J. Am. Coll. Cardiol, 72, pp.1278~1293 (2018)
126. Liu H, "Naringenin protects against hypertension by regulating lipid disorder and oxidative stress in a rat model", Kidney Blood Press Res, 47, pp.423~432 (2022)
127. Duan B, "Naringenin prevents pregnancy-induced hypertension via suppression of JAK", STAT3signalling pathway in mice, 2021, pp.75, e14509~
128. Wang Z, "Naringenin ameliorates renovascular hypertensive renal damage by normalizing the balance of renin-angiotensin system components in rats", Int. J. Med. Sci, 16, pp.644~653 (2019)
129. Ademola Adetokunbo Oyagbemi, "Antihypertensive power of Naringenin is mediated via attenuation of mineralocorticoid receptor(MCR)", angiotensin converting enzyme(ACE), Eur. J. Pharmacol, pp.2020, 880[DOI]
130. Hammer M, "Hyperglycemia and cancer : a state-of-the-science review", Oncol. Nurs. Forum, 46, pp.459~472 (2019)
131. Villegas-Valverde CC, "Strengthening national health priorities for diabetes prevention and management", MEDICC Rev, 20, pp.5~ (2018)
132. Mouri M, "StatPearls" (2023)
133. Yari Z, "New insight into diabetes management : from glycemic index to dietary insulin index", Curr. Diab. Rev, 16, pp.293~300 (2020)
134. Rawlings AM, "The association of late-life diabetes status and hyperglycemia with incident mild cognitive impairment and dementia : the ARIC study", Diab. Care, 42, pp.1248~1254 (2019)
135. Annadurai T, "Ameliorative effect of naringenin on hyperglycemia-mediated inflammation in hepatic and pancreatic tissues of Wistar rats with streptozotocin-nicotinamide-induced experimental diabetes mellitus", Free Radic. Res, 47, pp.793~803 (2013)
136. Annadurai T, "Antihyperglycemic and antioxidant effects of a flavanone, naringenin, in streptozotocin-nicotinamide-induced experimental diabetic rats", J. Physiol. Biochem, 68, pp.307~318 (2012)
137. Kometsi L, "By reducing oxidative stress, naringenin mitigates hyperglycaemia-induced upregulation of hepatic nuclear factor erythroid 2-related factor 2 protein", J. Pharm. Pharmacol, 72, pp.1394~1404 (2020)
138. Priscilla DH, "Flavanone naringenin : an effective antihyperglycemic and antihyperlipidemic nutraceutical agent on high fat diet fed streptozotocin induced type 2 diabetic rats", J. Funct. Foods, 14, pp.363~373 (2015)
139. Bortz JH, "CT Colonography for Radiographers", pp.277~290 (2023)
140. Rinella ME, "AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease", Hepatology, 77, pp.1797~1835 (2023)
141. Younossi Z, "Global burden of NAFLD and NASH : trends, predictions, risk factors and prevention", Nat. Rev. Gastroenterol. Hepatol, 15, pp.11~20 (2018)
142. Adams LA, "Nonalcoholic fatty liver disease increases risk of death among patients with diabetes : a community-based cohort study", Am. J. Gastroenterol, 105, pp.1567~1573 (2010)
143. Assini JM, "Naringenin prevents obesity, hepatic steatosis, and glucose intolerance in male mice independent of fibroblast growth factor 21", Endocrinology, 156, pp.2087~2102 (2015)
144. Wang Q, "Naringenin attenuates non-alcoholic fatty liver disease by down-regulating the NLRP3", NF-kappaB pathway in mice, 2020, pp.177, 1806~1821
145. Yang Y, "Naringenin attenuates non-alcoholic fatty liver disease by enhancing energy expenditure and regulating Autophagy via AMPK", Front. Pharmacol, 12, pp.687095~ (2021)
146. Yu RY, "Naringenin prevents NAFLD in the diet-induced C57BL", 6J obesity model by regulating the intestinal barrier function and microbiota, 2023, pp.105, 105578~
147. Kruk ME, "Mortality due to low-quality health systems in the universal health coverage era : a systematic analysis of amenable deaths in 137 countries", Lancet, 392, pp.2203~2212 (2018)
148. Blagov AV, "The role of macrophages in the pathogenesis of atherosclerosis", Cells, 12, pp.522~ (2023)
149. Wolf D, "Immunity and inflammation in atherosclerosis", Circ. Res, 124, pp.315~327 (2019)
150. Mulvihill EE, "Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice", Arterioscler. Thromb. Vasc. Biol, 30, pp.742-U224~ (2010)
151. Burke AC, "Naringenin enhances the regression of atherosclerosis induced by a chow diet in Ldlr(-", -)mice, 2019, pp.286, 60~70
152. Wang J, "Naringenin ameliorates vascular senescence and atherosclerosis involving SIRT1activation", J. Pharm. Pharmacol, 75, pp.1021~1033 (2023)
153. Guo MR, "Oral nanoparticles containing naringenin suppress atherosclerotic progression by targeting delivery to plaque macrophages", Nano Res, 16, pp.925~937 (2023)
154. Graham WV, "Update on Alzheimer's disease therapy and prevention strategies", Annu. Rev. Med, 68, pp.413~430 (2017)
155. Rajmohan R, "Amyloid-beta and phosphorylated Tau accumulations cause abnormalities at synapses of Alzheimer's disease neurons", J. Alzheimers Dis, 57, pp.975~999 (2017)
156. Tamagno E, "Oxidative stress increases expression and activity of BACE in NT2 neurons", Neurobiol. Dis, 10, pp.279~288 (2002)
157. Yang W, "Effect of naringenin on brain insulin signaling and cognitive functions in ICV-STZ induced dementia model of rats", Neurol. Sci, 35, pp.741~751 (2014)
158. Zhang N, "Protective role of Naringenin against Aβ-caused damage via ER and PI3K", Akt-mediated pathways, 2018, pp.38, 549~557
159. Heo HJ, "Naringenin from citrus junos has an inhibitory effect on acetylcholinesterase and a mitigating effect on amnesia", Dement. Geriatr. Cogn. Disord, 17, pp.151~157 (2004)
160. Lee S, "In silico docking and in vitro approaches towards BACE1 and cholinesterases inhibitory effect of citrus flavanones", Molecules, 23, pp.1509~ (2018)
161. Ghofrani S, "Naringenin improves learning and memory in an Alzheimer's disease rat model : insights into the underlying mechanisms", Eur. J. Pharmacol, 764, pp.195~201 (2015)
162. Zella MAS, "Novel immunotherapeutic approaches to target alphasynuclein and related neuroinflammation in Parkinson's disease", Cells, 8, pp.105~ (2019)
163. Sung VW, "Nonmotor symptoms in Parkinson's disease : expanding the view of Parkinson's disease beyond a pure motor, pure dopaminergic problem", Neurol. Clin, 31, pp.S1~S16 (2013)
164. Jayaraj RL, "Lycopodium attenuates loss of dopaminergic neurons by suppressing oxidative stress and neuroinflammation in a rat model of Parkinson's disease", Molecules, 24, pp.2182~ (2019)
165. Simola N, "The 6-hydroxydopamine model of Parkinson's disease", Neurotox Res, 11, pp.151~167 (2007)
166. Berry C, "Paraquat and Parkinson's disease", Cell Death Differ, 17, pp.1115~1125 (2010)
167. Cannon JR, "A highly reproducible rotenone model of Parkinson's disease", Neurobiol. Dis, 34, pp.279~290 (2009)
168. Lou H, "Naringenin protects against 6-OHDA-induced neurotoxicity via activation of the Nrf2", ARE signaling pathway, 2014, pp.79, 380~388
169. Zbarsky V, "Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease", Free Radic. Res, 39, pp.1119~1125 (2005)
170. Ahmad MH, "Naringenin alleviates paraquat-induced dopaminergic neuronal loss in SH-SY5Y cells and a rat model of Parkinson's disease", Neuropharmacology, 201, pp.108831~ (2021)
171. Dashputre NL, "Fabrication of nanoparticulate system for oral delivery of Naringenin against paraquat-induced Parkinson's disorder in Wistar rats", Eur. J. Med. Chem. Rep, 8, pp.100105~ (2023)
172. Madiha S, "Naringenin, a functional food component, improves motor and non-motor symptoms in animal model of parkinsonism induced by rotenone", Plant Foods Hum. Nutr, 78, pp.654~661 (2023)
173. Sonia Angeline M, "Sesamol and naringenin reverse the effect of rotenone-induced PD rat model", Neuroscience, 254, pp.379~394 (2013)

관련 논문AI추천